Competitive Landscape of Liquid Biopsy Market, Forecast by Recent Development, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue

Liquid Biopsy Market Companies Analysis

The Liquid Biopsy industry is expected to expand lucratively to an estimated value of US$ 15.46 Billion by 2033, from US$ 4.29 Billion in 2024. This expansion reflects a compound annual growth rate (CAGR) of 15.30% between 2025 and 2033.

Due to its minimally invasive nature and capacity to identify genetic abnormalities and cancer in blood samples, the liquid biopsy market is expanding quickly. It makes it possible for early diagnosis, real-time tumor progression tracking, and therapy efficacy evaluation. Oncology is using the technique more and more to find exosomes, cell-free DNA (cfDNA), and circulating tumor cells (CTCs), which can help manage the disease.

The market is expanding due in large part to rising cancer prevalence, genomics advancements, and the growing need for personalized medicine. Liquid biopsy also lessens the necessity for conventional surgical biopsies, which enhances diagnostic effectiveness and patient comfort. It is anticipated that ongoing innovation, regulatory clearances, and wider clinical use will support market expansion in a variety of international healthcare contexts. Leading World's Top Electric Vehicle (EV) Companies.

List of Leading Companies in the Liquid Biopsy Market

Roche Diagnostics

Establishment: 1896

Headquarters: Switzerland

Roche Diagnostics International Ltd (Roche Diagnostics), a company of F. Hoffmann-La Roche Ltd, provides diagnostic system solutions for clinics, labs, and doctor's offices. The company develops, produces, and maintains equipment and software systems for bioanalytical research and in-vitro diagnostics. It also offers workflow solutions, test systems, diagnostic analysis systems, and molecular diagnostic reagents. Its primary products are point-of-care testing equipment and blood glucose meters. Among the customers the company provides its products and services to include hospitals, commercial diagnostic labs, physicians, researchers, and pharmacists. Roche Diagnostics' main office is situated in Rotkreuz, Switzerland.

Exact Sciences (Genomic Health)

Establishment: 1995

Headquarters: United States of America

Revenue: $2.8B in 2023

The molecular diagnostic industry Exact Sciences Corp (Exact Sciences) is committed to developing assays for various cancer types. The primary product of the company is the Cologuard test, a non-invasive stool-based deoxyribonucleic acid (DNA) screening method approved by the US FDA and advised for the early detection of colorectal cancer and pre-cancer. It pursues a multi-target approach to find hemoglobin and DNA biomarkers associated with colorectal cancer. Moreover, the company offers Oncotype DX gene expression tests for prostate, breast, and colon cancers as well as the liquid-based Oncotype DX AR-V7 Nucleus Detect test for advanced stage prostate cancer. Its manufacturing and laboratory facilities are located in Madison, Wisconsin, to handle Cologuard tests. Exact Sciences' headquarters are located in Madison, Wisconsin, in the United States.

Thermo Fisher Scientific Inc.

Establishment: 2006

Headquarters: United States of America

Revenue: $42.9B in 2023

In addition to analytical instruments and life sciences solutions, Thermo Fisher Scientific Inc. (Thermo Fisher) offers laboratory, pharmaceutical, biotechnology, and specialty diagnostic services. Its products include chemicals, cell culture materials, tools for protein and cell analysis, therapeutic and diagnostic tools, devices for chromatography and mass spectrometry, items for molecular biology and nucleic acid analysis, and laboratory supplies, equipment, and instruments. The company distributes its products to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research organizations, and government agencies under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD brands. It sells its products through independent distributors, online sales, customer service representatives, and direct salespeople. Thermo Fisher's headquarters are located in Waltham, Massachusetts, in the United States.

Bio-Rad Laboratories Inc.

Establishment: 1952

Headquarters: United States of America

Revenue: $2.6B in 2023

Bio-Rad Laboratories Inc. (Bio-Rad) develops, manufactures, and markets instruments, software, consumables, and reagents for use in life science research and clinical diagnostics. Digital PCR, blood type and antibody detection systems, antibodies, autoimmune testing kits, and cell isolation and analysis tools are some of its goods. The company's solutions are utilized in a variety of sectors, including mutation detection, immunology, gene expression analysis, cell research, and bioprocess analytics. Hospitals, commercial and public health labs, academic institutions and research centers, diagnostic manufacturers, and companies in the food, chemical, pharmaceutical, and biotechnology industries are among its clients. Bio-Rad sells its products through direct sales channels, brokers, distributors, agencies, and resellers. The company has operations in the United States, Germany, France, China, and Singapore, among other countries. The headquarters of Bio-Rad are located in the US city of Hercules, California.

Biocept, Inc.

Establishment: 1997

Headquarters: United States of America

Molecular diagnostics is the area of expertise for the company Biocept Inc. (Biocept). It develops and sells proprietary circulating tumor cell (CTC) and circulating tumor DNA tests using a standard blood sample. The company offers tests for solid tumor indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. OncoCEE technology, related equipment, and analytical tools are offered by Biocept for genetic characterization and the discovery of rare events. The company's OncoCEE, Target Selector, and CEE-Sure systems modify rare cell collecting and analysis methods. It also offers cancer diagnostic tests to hospitals, cancer centers, and oncologists and other healthcare providers. Furthermore, Biocept provides research and clinical trial services to pharmaceutical and biopharmaceutical companies as well as clinical research institutions. The headquarters of Biocept are located in the US city of San Diego, California.

Laboratory Corporation of America Holdings (Labcorp) Recent Developments in Liquid Biopsy Market

In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two innovative additions aimed at advancing cancer diagnostics. The first offering, Labcorp Plasma Detect, is a clinical test developed to assess the risk of disease recurrence in patients with stage III colon cancer, enabling more personalized post-treatment care. The second, PGDx elio plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test designed for pan-solid tumors. This test assists clinicians in identifying patients who may be eligible for specific targeted therapies, thereby improving treatment precision and patient outcomes. Together, these advancements reinforce Labcorp's commitment to expanding access to advanced molecular diagnostics and supporting precision medicine in oncology through cutting-edge liquid biopsy technologies.

Tempus AI Inc. Recent Developments in Liquid Biopsy Market

In January 2025, Tempus AI, Inc. announced the launch of its FDA-approved next-generation sequencing (NGS)-based in vitro diagnostic test, xT CDx, now available to all ordering clinicians across the United States. Designed to deliver comprehensive genomic insights, xT CDx utilizes one of the largest FDA-approved gene panels currently on the market, enabling detailed analysis of multiple genomic alterations in a single test. The platform supports precision oncology by helping clinicians identify actionable mutations and tailor personalized treatment strategies for patients with various cancers. By integrating advanced NGS technology with clinical decision support, xT CDx aims to enhance diagnostic accuracy, improve therapy selection, and optimize patient outcomes. This launch underscores Tempus AI's commitment to advancing precision medicine and expanding access to innovative genomic testing nationwide.

Sustainability Analysis of Natera Inc.

Natera Inc. has demonstrated a strong commitment to sustainability through comprehensive environmental, social, and governance (ESG) initiatives. In 2024, the company achieved a 31% reduction in kit waste, eliminating nearly 1 million pounds of waste. Additionally, Natera contributed over 22,000 volunteer hours to communities globally, reflecting its dedication to social responsibility.

The company has also made significant strides in environmental sustainability. Natera achieved an approximately 8% reduction in Scope 1 and 2 greenhouse gas emissions since 2021 through increased energy efficiency. Furthermore, its Austin and San Carlos facilities received My Green Lab certifications, and the company earned local green business certifications, underscoring its commitment to sustainable operations.

Natera's sustainability efforts are further supported by its collaboration with South Pole, a climate consulting firm. This partnership guided Natera in performing its first full greenhouse gas accounting for scopes 1, 2, and 3 emissions, marking a crucial step in its journey toward net-zero emissions.

In summary, Natera Inc. is proactively integrating sustainability into its operations, demonstrating leadership in environmental stewardship, social responsibility, and governance.

Initiatives for Environmental Sustainability of Johnson & Johnson

By 2025, J&J plans to get all of its electricity from renewable sources, and by 2030, it wants to cut its absolute Scope 1 and 2 greenhouse gas emissions by 44% from a base year of 2021. Additionally, the firm wants to achieve net-zero emissions throughout its value chain by 2045 and wants 80% of its suppliers to establish science-based targets by 2028. By 2024, almost 88% of J&J's electricity demands will be satisfied by renewable sources worldwide, with Europe, the US, and Canada reaching 100% renewable electricity. In 16 countries, the company has completed 15 off-site renewable electricity purchase agreements and installed more than 40 on-site renewable energy systems.

Product profile of QIAGEN N.V.

Sample Collection and Stabilization:

• PAXgene Urine Liquid Biopsy Set: Facilitates urine collection and stabilization of cell-free DNA (cfDNA), minimizing degradation and microbial growth during storage. Compatible with downstream applications such as digital PCR and next-generation sequencing (NGS).

Nucleic Acid Extraction:

• QIAamp Circulating Nucleic Acid Kit: Designed for manual extraction of cfDNA from plasma, serum, or urine, providing high yields suitable for various molecular analyses.
• QIAseq cfDNA All-in-One Kit: Optimized for cfDNA analysis using NGS platforms, offering streamlined workflows for comprehensive genomic profiling.

SWOT Analysis of Guardant Health Inc.

Strength - Market Leadership in Liquid Biopsy

Guardant Health Inc. has established itself as a market leader in liquid biopsy, pioneering non-invasive cancer diagnostics with its Guardant360 and GuardantOMNI tests. These tests provide comprehensive genomic profiling across multiple cancer types, enabling personalized treatment strategies and improving patient outcomes. The company's robust intellectual property portfolio, including over 230 patents worldwide, reinforces its technological edge, allowing it to maintain a competitive advantage in the precision oncology space. Additionally, Guardant Health's substantial investment in research and development ensures continuous innovation, enhancing test accuracy, reliability, and adoption across healthcare providers globally. This strong technological foundation positions Guardant Health as a trusted partner for clinicians and researchers.

Opportunity - Expansion through Multi-Cancer Screening

The development of the Shield multi-cancer screening test presents Guardant Health with a significant growth opportunity. This test aims to detect early signals of multiple cancers from a single blood sample, potentially revolutionizing early cancer detection. Expanding this technology into global markets, especially in regions with growing healthcare infrastructure, can diversify revenue streams and increase market penetration. Strategic collaborations with hospitals, research institutions, and healthcare providers further enhance accessibility and integration into routine clinical workflows. As awareness and adoption of non-invasive cancer diagnostics increase, Guardant Health is well-positioned to capture a larger share of the precision oncology market.

SWOT Analysis of Ilumina Inc.

Strength - Leadership in Genomic Sequencing Technology

Illumina Inc. has firmly established itself as a global leader in genomic sequencing, offering cutting-edge next-generation sequencing (NGS) platforms such as NovaSeq, MiSeq, and NextSeq. These platforms provide high-throughput, accurate, and cost-effective genomic analysis, making them widely adopted in research, clinical diagnostics, and consumer genomics. Illumina's strong intellectual property portfolio, including patents covering sequencing technologies, reagents, and bioinformatics, creates a significant competitive advantage and high barriers to entry for new players. The company's extensive R&D investment ensures continuous innovation, enhancing performance, accuracy, and scalability. Additionally, strategic partnerships with pharmaceutical companies, academic institutions, and healthcare providers amplify the adoption of its solutions globally, positioning Illumina as a trusted and dominant player in the genomics ecosystem.

Opportunity - Expansion in Personalized Medicine and Diagnostics

The growing demand for precision medicine, particularly in oncology, rare diseases, and prenatal testing, presents Illumina with substantial growth opportunities. By leveraging its advanced sequencing platforms, Illumina can provide comprehensive genomic insights that guide targeted therapies, improve patient outcomes, and support early disease detection. Expanding the application of NGS technologies into clinical diagnostics allows the company to tap into the rapidly growing healthcare market. Collaborations with pharmaceutical companies for companion diagnostics and integration into clinical trials offer additional revenue streams and strengthen its industry footprint. Furthermore, increasing global awareness and adoption of genomic testing, combined with technological advancements that reduce sequencing costs, positions Illumina to capture a larger share of the personalized medicine and diagnostics market.

Liquid Biopsy Market & Forecast

• Historical Trends
• Forecast Analysis

Market Share Analysis - Liquid Biopsy

Company Analysis - Guardant Health Inc.

Overview

• Company History and Mission
• Business Model and Operations
• Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

1. Guardant Health Inc.

2. Foundation Medicine Inc. (Roche)

3. Natera Inc.

4. Illumina Inc.

5. Exact Sciences Corporation

6. Tempus AI Inc.

7. Thermo Fisher Scientific Inc.

8. Bio-Rad Laboratories Inc.

9. QIAGEN N.V.

10. Caris Life Sciences

11. MDxHealth SA

12. Biocept Inc.

13. Johnson & Johnson (Janssen Diagnostics)

14. Laboratory Corporation of America Holdings (Labcorp)

15. Epigenomics AG

16. F. Hoffmann-La Roche Ltd.

17. Bio-Rad Laboratories

18. Johnson & Johnson

19. Guardant Health

20. Illumina, Inc.